Kishor Salunkhe

The objective of this work was to develop and validate simple, rapid and accurate chromatographic method for determination of Desvenlafaxine succinate in solid dosage form. This RP-HPLC method was based on Reversed Phase High Performance Liquid Chromatography, on ODS C18 RP column (250 mm × 4.6 mm i.d., 5 μ), using Acetonitrile: Ammonium Phosphate buffer (pH 3.0) (70:30 v/v) as the mobile phase, at a flow rate of 1 mL/min at ambient temperature. Quantification was achieved by UV detection at 220 nm over a concentration range of 20-160 μg/mL for Desvenlafaxine succinate. The mean retention time for Desvenlafaxine succinate was found to be 2.44 min. The amount of Desvenlafaxine succinate estimated as percentage label claim was found to be 99.67. Key words: RP-HPLC, Desvenlafaxine succinate, marketed formulation.

Over the past few decades, there has been an increased  interest for innovative drug delivery systems to improve safety, efficacy and patient compliance, thereby increasing the product patent life cycle. There are novel types of dosage forms that act very quickly after administration. The basic approach used in development tablets is the use of superdisintegrants like Cross linked carboxymelhyl cellulose (Croscarmeliose), Sodium starch glycolate (Primogel, Explotab), Polyvinylpyrrolidone (Polyplasdone) etc. which provide instantaneous disintegration of tablet after administration. Immediate release liquid dosage forms and parenteral dosage form have also been introduced for treating patients. Liquid dosage form can be suspensions with typical dispersion agents like hydroxypropyl methylcellulose, AOT (dioctylsulfosuccinate) etc. The development of immediate release therapy also provides an opportunity for a line extension in the marketplace, A wide range of drugs (e.g., neuroleptics, cardiovascular drugs, analgesics, antihistamines, and drugs can be considered candidates for this dosage form. In this regard, immediate release formulations are similar to many sustained release formulations that are now commonly available. oral film dosage form not only has certain advantages of other fast disintegrating systems but also satisfies the unmet needs of the market. The present review emphasizes on the potential benefits, design and development of robust, stable, and  innovative orally immediate and their future  scenarios on a global market as a pharmaceutical dosage form.